Gustave Roussy, leading European comprehensive cancer center, chooses Elekta’s Versa HD

PARIS, September 1, 2015 – Gustave Roussy has awarded Elekta (EKTA-B.ST) with an order for four Versa HD™ linear accelerators, replacing their existing installed base of competing systems.

Gustave Roussy, a premier European comprehensive cancer center, started a program in 2013 to gain a clear leadership in the field of radiotherapy. Acquiring Versa HD will help it achieve its ambition to place innovation at the heart of a human, scientific and technological revolution in the fight against cancer.

Versa HD is designed to be the most sophisticated, high-versatility treatment system, giving clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.

Ian Alexander, Chief Commercial Officer at Elekta, says: “Elekta shares Gustave Roussy’s approach to oncology, which embraces values such as innovation, dynamism, and cooperation. This new partnership will benefit the hospital staff as well as the thousands of patients they treat every year.”

The hospital also installed Elekta’s MOSAIQ® oncology information system two years ago. The order for the Versa HD systems was booked in Elekta’s first quarter for the fiscal year 2015/16.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on September 1, 2015.
 
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Tags:

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Subscribe

Documents & Links